Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL PSORIASIS TREATMENT MARKET, BY DRUG CLASS
6.1. Overview
6.2. Tumour Necrosis Factor Inhibitors
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.2.1. Adalimumab
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.2.2. Infliximab
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.2.3. Etanercept
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.3. Anticholinergics
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.3.1. Ustekinumab
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.3.2. SecU.K.inumab
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.3.3. Ixekizumab
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.3.4. Brodalumab
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.4. Vitamin D Analogues
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.4.1. Calcitriol
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.4.2. Calcipotriol
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.4.3. Tacalcitol
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7. GLOBAL PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE
7.1. Overview
7.2. Topicals
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.2.1. Over-The-Counter (OTC) Topicals
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.2.2. Topical Non-Steroids
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.2.3. Topical Steroids
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.3. Systemic
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.3.1. Retinoid
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.3.2. Cyclosporine
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.3.3. Methotrexate
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.4. Biologics
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.4.1. Tumour Necrosis Factor Alpha (TNF-α) Inhibitors
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.4.2. InterleU.K.in 12 and 23 (IL-12/23) Inhibitors
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.4.3. InterleU.K.in 17 (IL-17) Inhibitor
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.4.4. T Cell Inhibitor
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
8. GLOBAL PSORIASIS TREATMENT MARKET, BY REGION
8.1. Overview
8.2. Americas
8.2.1. North America
8.2.1.1. US
8.2.1.2. Canada
8.2.2. Latin America
8.3. Europe
8.3.1. Western Europe
8.3.1.1. Germany
8.3.1.2. France
8.3.1.3. Italy
8.3.1.4. Spain
8.3.1.5. UK
8.3.1.6. Rest of Western Europe
8.3.2. Eastern Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle East & Africa
8.5.1. Middle East
8.5.2. Africa
9. COMPANY LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Psoriasis Treatment Market
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Global Psoriasis Treatment Market
9.7. Key Developments and Growth Strategies
9.7.1. New Application Launch/Service Deployment
9.7.2. Mergers and Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix & Market Ratio
9.8.1. Sales & Operating Income 2020
9.8.2. Major Players R&D Expenditure 2020
9.9. Major Players Capital Market Ratio
10. COMPANY PROFILES
10.1. Novartis International AG
10.1.1. Company Overview
10.1.2. Application Type Overview
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. UCB
10.2.1. Company Overview
10.2.2. Application Type Overview
10.2.3. Financial Overview
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. AstraZeneca
10.3.1. Company Overview
10.3.2. Application Type Overview
10.3.3. Financial Overview
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Celgene Corporation.
10.4.1. Company Overview
10.4.2. Application Type Overview
10.4.3. Financial Overview
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Johnson & Johnson
10.5.1. Company Overview
10.5.2. Application Type Overview
10.5.3. Financial Overview
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. Pfizer Inc
10.6.1. Company Overview
10.6.2. Application Type Overview
10.6.3. Financial Overview
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Merck and Co. Inc
10.7.1. Company Overview
10.7.2. Application Type Overview
10.7.3. Financial Overview
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. AbbVie
10.8.1. Company Overview
10.8.2. Application Type Overview
10.8.3. Financial Overview
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Amgen.
10.9.1. Company Overview
10.9.2. Application Type Overview
10.9.3. Financial Overview
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Others
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL PSORIASIS TREATMENT MARKET SYNOPSIS, 2022-2030
TABLE 2 GLOBAL PSORIASIS TREATMENT MARKET ESTIMATES & FORECAST, 2022-2030 (USD MILLION)
TABLE 3 GLOBAL PSORIASIS TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 4 GLOBAL PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)
TABLE 5 GLOBAL PSORIASIS TREATMENT MARKET, BY REGION, 2022-2030 (USD MILLION)
TABLE 6 NORTH AMERICA: PSORIASIS TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 7 NORTH AMERICA: PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)
TABLE 8 US: PSORIASIS TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 9 US: PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)
TABLE 10 CANADA: PSORIASIS TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 11 CANADA: PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)
TABLE 12 LATIN AMERICA: PSORIASIS TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 13 LATIN AMERICA: PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)
TABLE 14 EUROPE: PSORIASIS TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 15 EUROPE: PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)
TABLE 16 WESTERN EUROPE: PSORIASIS TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 17 WESTERN EUROPE: PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)
TABLE 18 EASTERN EUROPE: PSORIASIS TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 19 EASTERN EUROPE: PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)
TABLE 20 ASIA-PACIFIC: PSORIASIS TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 21 ASIA-PACIFIC: PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA: PSORIASIS TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA: PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCES
FIGURE 2 MARKET STRUCTURE OF THE GLOBAL PSORIASIS TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS OF THE GLOBAL PSORIASIS TREATMENT MARKET
FIGURE 4 GLOBAL PSORIASIS TREATMENT MARKET SHARE, BY DRUG CLASS, 2020 (%)
FIGURE 5 GLOBAL PSORIASIS TREATMENT MARKET SHARE, BY TREATMENT TYPE, 2020 (%)
FIGURE 6 GLOBAL PSORIASIS TREATMENT MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 AMERICAS: PSORIASIS TREATMENT MARKET SHARE BY REGION, 2020 (%)
FIGURE 7 NORTH AMERICA: PSORIASIS TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 8 EUROPE: PSORIASIS TREATMENT MARKET SHARE, BY REGION, 2020 (%)
FIGURE 9 WESTERN EUROPE: PSORIASIS TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 10 ASIA-PACIFIC: PSORIASIS TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 MIDDLE EAST & AFRICA: PSORIASIS TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 GLOBAL PSORIASIS TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 13 NOVARTIS INTERNATIONAL AG: KEY FINANCIALS
FIGURE 14 NOVARTIS INTERNATIONAL AG: SEGMENTAL REVENUE
FIGURE 15 NOVARTIS INTERNATIONAL AG: REGIONAL REVENUE
FIGURE 16 UCB
FIGURE 17 ASTRAZENECA
FIGURE 18 CELGENE CORPORATION
FIGURE 19 JOHNSON & JOHNSON
FIGURE 20 PFIZER INC
FIGURE 21 MERCK AND CO. INC
FIGURE 22 ABBVIE
FIGURE 23 AMGEN
FIGURE 24 ELI LILLY AND COMPANY